Compare LENZ & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LENZ | EQ |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.8M | 89.4M |
| IPO Year | 2021 | 2018 |
| Metric | LENZ | EQ |
|---|---|---|
| Price | $3.22 | $1.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $23.86 | $8.56 |
| AVG Volume (30 Days) | ★ 744.4K | 441.5K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,088,000.00 | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $152.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.12 | $1.16 |
| 52 Week High | $32.92 | $6.20 |
| Indicator | LENZ | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 32.50 | 34.91 |
| Support Level | N/A | N/A |
| Resistance Level | $6.11 | $1.51 |
| Average True Range (ATR) | 0.21 | 0.13 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 13.89 | 23.20 |
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.